Home / Gabapentin / Canada
CA ATC N02BF01 · updated 2 Nov 2026
Gabapentin shortage in Canada
Is there a Gabapentin shortage in Canada?
Yes. As of 2 Nov 2026, 32 Gabapentin products are reported short in Canada, the first since 11 Apr 2014. The company estimate for the return is 20 Nov 2026 (latest 27 Jan 2027). Main reason: manufacturing problem.
Also short in Italy, Spain, Ireland, Austria, Belgium, Czechia, Norway, Sweden. All countries.
Affected products in Canada
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CA | RIVA-GABAPENTIN (100 & 500) | LABORATOIRE RIVA INC | 11 Apr 2014 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | RIVA-GABAPENTIN (100) | LABORATOIRE RIVA INC | 11 Apr 2014 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | ACT GABAPENTIN (500) | ACTAVIS PHARMA COMPANY | 18 Aug 2017 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | MAR-GABAPENTIN (500 TABLET) | MARCAN PHARMACEUTICALS INC | 10 Apr 2019 | not given | Other Other (Please describe in comments) |
| CA | MAR-GABAPENTIN (100 Tablet) discontinuation | MARCAN PHARMACEUTICALS INC | 12 Feb 2020 | not given | Other Other (Please describe in comments) |
| CA | MAR-GABAPENTIN (100 Tablet) discontinuation | MARCAN PHARMACEUTICALS INC | 12 Feb 2020 | not given | Other Other (Please describe in comments) |
| CA | MAR-GABAPENTIN (100 Tablet) discontinuation | MARCAN PHARMACEUTICALS INC | 14 Feb 2020 | not given | Other Other (Please describe in comments) |
| CA | MAR-GABAPENTIN (500 TABLET) | MARCAN PHARMACEUTICALS INC | 21 Feb 2020 | not given | Other Other (Please describe in comments) |
| CA | BIO-GABAPENTIN (100) | BIOMED PHARMA | 4 Nov 2020 | not given | Distribution or logistics Delay in shipping of the drug |
| CA | BIO-GABAPENTIN (100) | BIOMED PHARMA | 5 Nov 2020 | not given | Distribution or logistics Delay in shipping of the drug |
| CA | BIO-GABAPENTIN (100) | BIOMED PHARMA | 5 Nov 2020 | not given | Distribution or logistics Delay in shipping of the drug |
| CA | BIO-GABAPENTIN (100) | BIOMED PHARMA | 30 May 2021 | not given | Distribution or logistics Delay in shipping of the drug |
| CA | GABAPENTIN TABLETS USP (100) | ACCORD HEALTHCARE INC | 5 May 2023 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | GABAPENTIN CAPSULES USP (100) | ACCORD HEALTHCARE INC | 29 Dec 2023 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | GABAPENTIN CAPSULES USP (100) | ACCORD HEALTHCARE INC | 19 Jan 2024 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | GABAPENTIN CAPSULES USP (100) | ACCORD HEALTHCARE INC | 17 May 2024 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | GABAPENTIN (100) | SANIS HEALTH INC | 23 Aug 2024 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | NEURONTIN (100BT CA) | BGP PHARMA ULC | 5 Jan 2026 | 5 Jan 2027 | Active ingredient shortage Shortage of an active ingredient |
| CA | NEURONTIN (100BTL) | BGP PHARMA ULC | 2 Feb 2026 | 5 Jan 2027 | Active ingredient shortage Shortage of an active ingredient |
| CA | APO-GABAPENTIN (100 BTL) | APOTEX INC | 3 Feb 2026 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | GLN-GABAPENTIN (100s) | GLENMARK PHARMACEUTICALS CANADA INC. | 30 May 2026 | not given | Other Other (Please describe in comments) |
| CA | TEVA-GABAPENTIN (500) | TEVA CANADA LIMITED | 3 Jun 2026 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | PRO-GABAPENTIN (100) | PRO DOC LIMITEE | 19 Jun 2026 | 27 Jan 2027 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | GABAPENTIN (100) | SANIS HEALTH INC | 3 Jul 2026 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | PRO-GABAPENTIN (100) | PRO DOC LIMITEE | 29 Jul 2026 | 27 Jan 2027 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | GLN-GABAPENTIN (100s) | GLENMARK PHARMACEUTICALS CANADA INC. | 30 Jul 2026 | not given | Other Other (Please describe in comments) |
| CA | APO-GABAPENTIN (500 BTL) | APOTEX INC | 29 Sep 2026 | 20 Nov 2026 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-GABAPENTIN (100 BTL) | APOTEX INC | 6 Oct 2026 | 20 Nov 2026 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-GABAPENTIN (500 BTL) | APOTEX INC | 6 Oct 2026 | 20 Nov 2026 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-GABAPENTIN (100 BTL) | APOTEX INC | 13 Oct 2026 | 20 Nov 2026 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-GABAPENTIN (100 BTL) | APOTEX INC | 27 Oct 2026 | 20 Nov 2026 | Manufacturing problem Disruption of the manufacture of the drug |
| CA | NEURONTIN (100BT) anticipated | BGP PHARMA ULC | 15 Dec 2026 | 5 Jan 2027 | Manufacturing problem Disruption of the manufacture of the drug |
Source
Health Canada, Health Product Shortages Canada. Official list. Mandatory company reports since 2017: actual and anticipated shortages, plus products about to be discontinued.